Trial Profile
Phase I trial of IPH 2102 in patients with multiple myeloma.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2011
Price :
$35
*
At a glance
- Drugs Lirilumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Innate Pharma
- 22 Mar 2011 New trial record